PErsonalized TReatment for Endometrial Carcinoma

Launched by UNIVERSITY OF HELSINKI · Dec 8, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at different treatment options for women with early-stage endometrial cancer, specifically types that are considered high-risk for recurrence. The researchers want to see how well two main types of treatment work: one group of participants will receive chemotherapy, while another group will get a combination of chemotherapy and radiation. Additionally, they will compare two types of radiation therapy—vaginal brachytherapy and whole pelvic radiotherapy—based on specific cancer characteristics.

To be eligible for this trial, participants should be women aged 18 to 100 who have been diagnosed with stage I or II high-risk endometrial cancer. They should have a good overall health status and should not have had certain previous cancers or treatments that could interfere with the study. If you decide to participate, you’ll be closely monitored throughout the process and will contribute to important research that could help improve treatment for future patients with similar conditions.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age 18 to 100 years
• • WHO performance status 0 to 2
• • Stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma
• Exclusion Criteria:
• • Age \<18 years or \>100 years
• • WHO performance status \>2
• • Uterine sarcoma
• • A history of malignancy within 5 years
• • Previous pelvic radiotherapy
• • An interval of \>30 days between surgery and start of chemotherapy or \>8 weeks between surgery and start of radiotherapy (longer intervals may be permitted with investigator´s approval)

Trial Officials